FDA Clinical Trials Phase 3 & Biotech Catalyst Radar
Pricing
from $16.00 / 1,000 results
FDA Clinical Trials Phase 3 & Biotech Catalyst Radar
Real-time clinical trial tracker monitoring FDA Phase 3 completions, PDUFA dates, and biotech stock catalysts before market open.
Pricing
from $16.00 / 1,000 results
Rating
0.0
(0)
Developer
Robin world
Maintained by CommunityActor stats
0
Bookmarked
2
Total users
1
Monthly active users
4 days ago
Last modified
Categories
Share
๐งฌ FDA Clinical Trials & Biotech Catalyst Tracker
Real-time quantitative intelligence on Phase 1โ4 clinical trials, estimated readout catalyst dates, investigational drug pipelines, and pharmaceutical sponsors. Built specifically for biotech hedge funds, healthcare equity analysts, and clinical trial recruiters.
๐ก Why Choose This Actor?
Biotech catalysts (Phase 2 proof-of-concept and Phase 3 pivotal data readouts) are the single largest drivers of volatility and multi-bagger returns in healthcare equities. Traditional intelligence feeds charge steep enterprise subscriptions:
| Feature / Metric | Enterprise Biotech Terminals (BioPharmCatalyst / Evaluate) | Custom In-House Python Scraper | FDA Clinical Trials & Biotech Catalyst Tracker |
|---|---|---|---|
| Monthly Pricing | $499 โ $1,999 / month (Locked contract) | $0 + Dev maintenance time & IP block risk | Pay-Per-Event ($0.0120 / trial) (No commitment) |
| Data Freshness | Daily batch sync | Fragile / Breaks on API changes | Real-time live NIH ClinicalTrials.gov v2 sync |
| Catalyst Date Modeling | Manual tagging | None | Automated Primary Completion Catalyst Window |
| Free Trial | Demo call required | None | $5.00 Free Trial Credit (Up to 400 trials free) |
| Export Formats | CSV / Excel only | Manual setup | JSON, CSV, Excel, Webhooks, Python API |
๐ฏ Key Use Cases
- Biotech Hedge Funds & Quant Traders:
- Screen Phase 3 pivotal completion dates (
primary_completion_date) to forecast binary catalyst volatility events. - Track sponsor pipeline changes (e.g. Pfizer, Eli Lilly, Biogen, Vertex) for pipeline expansion or trial discontinuations.
- Screen Phase 3 pivotal completion dates (
- Clinical Research Organizations (CROs):
- Identify active recruiting trials by therapeutic area (
condition) and competitor trial density.
- Identify active recruiting trials by therapeutic area (
- Medical Device & Pharma Intelligence:
- Monitor investigational drug combinations and competitive mechanism-of-action landscape.
๐ฅ Input Parameters
| Parameter | Type | Default | Description |
|---|---|---|---|
condition | String | "Cancer" | Disease or therapeutic condition (e.g. Cancer, Alzheimer, Obesity, Rare Disease, or blank for all). |
phase | Select | "PHASE3" | Development phase filter: ALL, PHASE1, PHASE2, PHASE3, PHASE4. |
status | Select | "RECRUITING" | Trial status: ALL, RECRUITING, ACTIVE_NOT_RECRUITING, COMPLETED. |
sponsor | String | "" | Optional sponsor filter (e.g. Pfizer, Eli Lilly, Moderna, Novartis). |
maxItems | Integer | 50 | Maximum number of clinical trial records to extract (up to 500). |
๐ค Output Data Format (JSON Sample)
[{"nct_id": "NCT05423184","brief_title": "A Phase 3 Study of Pembrolizumab Combination in Patients With Advanced Solid Tumors","official_title": "A Randomized, Double-Blind, Phase 3 Study Comparing Pembrolizumab Plus Chemotherapy Versus Standard Care","phases": "Phase 3","overall_status": "RECRUITING","lead_sponsor": "Merck Sharp & Dohme LLC","collaborators": ["National Cancer Institute (NCI)"],"conditions": ["Non-Small Cell Lung Cancer", "Metastatic Carcinoma"],"interventions": ["Drug: Pembrolizumab", "Drug: Carboplatin"],"study_type": "INTERVENTIONAL","enrollment_count": 850,"start_date": "2023-01-15","primary_completion_date": "2026-11-30","completion_date": "2027-06-30","catalyst_timing": "๐ฅ Urgent Catalyst: Q4 2026 Expected Readout","brief_summary": "The purpose of this study is to evaluate the progression-free survival and overall survival...","study_url": "https://clinicaltrials.gov/study/NCT05423184","scraped_at": "2026-09-08T04:30:00+00:00"}]
๐ 1-Click Python Integration
from apify_client import ApifyClient# Initialize client with your Apify API Tokenclient = ApifyClient("YOUR_APIFY_TOKEN")# Run the FDA Clinical Trials & Biotech Catalyst Trackerrun = client.actor("robinworld/fda-clinical-trials-biotech-catalyst").call(run_input={"condition": "Oncology","phase": "PHASE3","status": "RECRUITING","maxItems": 50})# Fetch results from the default datasetfor item in client.dataset(run["defaultDatasetId"]).iterate_items():print(f"[{item['nct_id']}] {item['lead_sponsor']}: {item['brief_title'][:60]}...")print(f" ๐ Catalyst Window: {item['catalyst_timing']} | Readout: {item['primary_completion_date']}")
โ Frequently Asked Questions (FAQ)
Q: How often is the data updated?
Data is pulled in real-time from the official NIH ClinicalTrials.gov v2 REST API, reflecting all protocol amendments, status changes, and new submissions immediately.
Q: How is the catalyst window calculated?
The Actor extracts the official primaryCompletionDateStruct filed with the NIH protocol and maps it into quarterly financial catalyst milestones (Q1-Q4 YYYY).
Q: Can I run this on a scheduled basis?
Yes! You can configure an Apify Schedule (e.g. daily at 09:00 AM) to automatically push new Phase 2/3 trial readouts to your Slack, Discord, or database via Webhooks.